Biocon Biologics gains 1 per cent on partnering with Viatris; wins US Court decisions

The stock of Biocon gained 1.29 per cent to Rs 366.50 in today’s trading session.

Biocon Biologics gains 1 per cent on partnering with Viatris; wins US Court decisions  

Biocon Biologics, a subsidiary of Biocon announced on Friday that the US Court of Appeals for the Federal Circuit (USCAFC) has supported the decisions of the US Patent & Trademark Appeal Board for the unpatentability of five device patents for Sanofi’s Lantus SoloSTAR. The case was filed in April and May 2020.  

Viatris analyse patients for important medicines such as Semglee. The companies together launched their substitutable Semglee products (Insulin glargine-yfgn) last month, which are the first and currently, the only substitutable biosimilars to Lantus, providing a more reasonable opportunity for the millions of Americans living with diabetes. It helps the company in reaching out to the patients.  

Type 2 diabetes adults and pediatric patients with type 1 diabetes are treated with Lantus as an insulin drug for the control of high blood sugar. Lantus sells the product as a disposable injection pen (Lantus SoloSTAR). Sanofi’s total sales in the US ending September 30, 2021, were USD 5.1 billion for Lantus SoloSTAR 100 Units/ml.  

Viatris and Biocon Biologics, together, work for the manufacturing, development & marketing of insulin. Viatris has special marketing rights in the US, Canada, Australia, New Zealand, European Union, and European Free Trade Association countries. Biocon Biologics has exclusive commercialisation rights for Japan along with certain emerging markets.   

Biocon Limited is a global pharmaceutical company innovating in providing affordable generic & chronic conditions like diabetes, cancer, and autoimmune. It is also working on immunotherapy, which is under development. The stock of Biocon gained 1.29 per cent to Rs 366.50 in today’s trading session.